Biostar Pharmaceuticals (BSPM) Stock Price, News & Analysis

Company Overview

Biostar Pharmaceuticals, Inc. (OTCMKTS: BSPM) is a development-stage biopharmaceutical company focused on acquiring, licensing and advancing novel therapeutic candidates in oncology and metabolic disease. The company’s primary business activity involves identifying proprietary small-molecule and biologic compounds through collaborations with academic institutions, research organizations and biotech partners. Biostar aims to leverage cost-effective development pathways to progress its pipeline from preclinical research into early-stage clinical trials.

Through strategic licensing agreements, Biostar Pharmaceuticals builds a diversified portfolio of drug candidates targeting solid tumors, hematological malignancies and metabolic disorders. The company’s R&D strategy emphasizes preclinical validation, pharmacology studies and formulation development, with the goal of advancing select assets toward Phase 1 and Phase 2 clinical evaluations. By focusing on niche indications and leveraging external expertise, Biostar seeks to optimize capital efficiency and position its programs for potential out-licensing or co-development partnerships.

Biostar serves global markets via collaborative networks rather than direct commercial operations, enabling the company to tap into specialized research capabilities and manufacturing resources worldwide. While specific leadership details are not broadly publicized, the management team comprises professionals with backgrounds in drug discovery, regulatory affairs and business development. Biostar continues to explore new licensing opportunities and strategic alliances to expand its pipeline and move its therapeutic programs forward.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: N/A
• Volume: 6 shs
• Average Volume: 11 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BSPM Stock Analysis - Frequently Asked Questions

How were Biostar Pharmaceuticals' earnings last quarter?

Biostar Pharmaceuticals, Inc. (OTCMKTS:BSPM) issued its earnings results on Wednesday, November, 15th. The company reported ($0.50) EPS for the quarter.

How do I buy shares of Biostar Pharmaceuticals?

Shares of BSPM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biostar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biostar Pharmaceuticals investors own include Cellectar Biosciences (CLRB), HudBay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Cyclacel Pharmaceuticals (CYCC) and Synergy Pharmaceuticals (SGYP).

Company Calendar

• Last Earnings: 11/15/2017
• Today: 9/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BSPM
• CIK: N/A
• Web: biostarpharmaceuticals.com
• Phone: 862933686638
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 51.60